Bittersweet China
14/09/23 -"China has been and will be a growth market, and also when it comes to medtech. On the other hand, the Chinese government aims to root out deep-seated corruption. We have a strong belief that ..."
Pages
72
Language
English
Published on
14/09/23
You may also be interested by these reports :
30/10/26
Amplifon’s Q3 sales met expectations, while adjusted EBITDA missed. All regions recorded growth. Profitability improved, but full-year guidance ...
29/10/26
Clariane’s Q3 confirmed the operating turnaround: organic growth accelerated to 4.9%, occupancy reached 93% and France finally joined the party. The ...
28/10/26
The change in our NAV calculation reflects a change of analyst covering the stock. Our NAV/SOTP valuation is now based on a new breakdown separating ...
27/10/26
Despite some near-term caution (discussed in the EPS section), we continue to see sizeable upside for bioMerieux, supported by its dominance in ...